InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: None

Saturday, 11/04/2017 9:26:39 AM

Saturday, November 04, 2017 9:26:39 AM

Post# of 48316
OncoSec data continues to build for Keytruda combination, says Maxim Maxim analyst Jason McCarthy noted that OncoSec (ONCS) presented "positive" data demonstrating that at 6 months the combination of the company's TAVO with Merck's (MRK) Keytruda in melanoma patients that are non-responders to checkpoint therapy induced a best overall response rate of 50%. The Phase 2b registration study with Merck is now underway and good results would be a "significant incentive" for Merck to support the combination, said McCarthy, who keeps a Buy rating and $5 price target on OncoSec shares.

Read more at:
https://thefly.com/landingPageNews.php?id=2625658